NEURAXIS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.8 USD | +2.94% |
|
-2.44% | +4.87% |
| Jun. 07 | NeurAxis Submits Application to FDA to Expand IB-Stim Label | MT |
| May. 22 | Earnings Flash (NRXS) NEURAXIS Posts Q1 Revenue $646,635 | MT |
Valuation
| Fiscal Period: December | 2023 |
|---|---|
| Capitalization 1 | 14.12 |
| Enterprise Value (EV) 1 | 14.27 |
| P/E ratio | -0.59 x |
| Yield | - |
| Capitalization / Revenue | 5.74 x |
| EV / Revenue | 5.8 x |
| EV / EBITDA | -2.15 x |
| EV / FCF | -2,154,981 x |
| FCF Yield | -0% |
| Price to Book | -12.4 x |
| Nbr of stocks (in thousands) | 5,290 |
| Reference price 2 | 2.670 |
| Announcement Date | 4/16/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net sales 1 | 1.93 | 2.721 | 2.685 | 2.46 |
| EBITDA 1 | -4.085 | -2.933 | -3.335 | -6.624 |
| EBIT 1 | -4.121 | -2.97 | -3.372 | -6.664 |
| Operating Margin | -213.48% | -109.14% | -125.61% | -270.91% |
| Earnings before Tax (EBT) 1 | -3.726 | -3.028 | -4.78 | -14.63 |
| Net income 1 | -3.726 | -3.028 | -4.78 | -14.63 |
| Net margin | -193.04% | -111.27% | -178.05% | -594.57% |
| EPS 2 | -1.893 | -1.539 | -2.768 | -4.497 |
| Free Cash Flow | - | -1.087 | 2.989 | -6.621 |
| FCF margin | - | -39.93% | 111.33% | -269.15% |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 9/27/22 | 9/27/22 | 6/1/23 | 4/16/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q4 | 2024 Q1 |
|---|---|---|
| Net sales 1 | 0.5315 | 0.6466 |
| EBITDA | - | - |
| EBIT 1 | -1.623 | -1.832 |
| Operating Margin | -305.42% | -283.33% |
| Earnings before Tax (EBT) | - | - |
| Net income | - | - |
| Net margin | - | - |
| EPS | - | - |
| Dividend per Share | - | - |
| Announcement Date | 4/16/24 | 5/20/24 |
1USD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net Debt 1 | - | 0.12 | 0.35 | 0.15 |
| Net Cash position 1 | 1.58 | - | - | - |
| Leverage (Debt/EBITDA) | - | -0.0404 x | -0.1035 x | -0.022 x |
| Free Cash Flow | - | -1.09 | 2.99 | -6.62 |
| ROE (net income / shareholders' equity) | - | -740% | 149% | 419% |
| ROA (Net income/ Total Assets) | - | -105% | -188% | -419% |
| Assets 1 | - | 2.895 | 2.541 | 3.494 |
| Book Value Per Share 2 | 0.8300 | -0.4300 | -2.840 | -0.2200 |
| Cash Flow per Share 2 | 0.9600 | 0.1700 | 0.1300 | 0.0100 |
| Capex 1 | 0.03 | 0 | 0 | 0.03 |
| Capex / Sales | 1.44% | 0.05% | 0.05% | 1.25% |
| Announcement Date | 9/27/22 | 9/27/22 | 6/1/23 | 4/16/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +4.87% | 18.61M | |
| +75.69% | 12.57B | |
| -29.24% | 6.9B | |
| -8.77% | 5.69B | |
| +5.81% | 5.04B | |
| -17.16% | 4.69B | |
| +17.07% | 4.18B | |
| -18.25% | 3.86B | |
| -21.23% | 2.97B | |
| -1.73% | 1.99B |
- Stock Market
- Equities
- NRXS Stock
- Financials NeurAxis, Inc.
